Table 2

Evolution of ex vivo plasma ACE C-domain activity (HHL hydrolysis) in mice treated with RXP 407 and lisinopril

Treatment	Plasma ACE C-Domain Activity^2-a		AUC_15–60^2-a
Treatment	15 min^2-b	30 min^2-b	AUC_15–60^2-a	45 min^2-b	60 min^2-b
	Hippuric acid, nmol/ml/min		nmol/ml
Control	78.5 ± 13.5^2-c	82.6 ± 21.3^2-c	75.2 ± 13.4^2-c	71.8 ± 25.9^2-c	3495
RXP 407
0.1 mg/kg	85.8 ± 26.5^2-c	89.9 ± 28.3^2-c	74.6 ± 20.1^2-c	83.2 ± 23.6^2-c	3737
0.5 mg/kg	93.5 ± 33.7^2-c	78.4 ± 16.0^2-c	94.2 ± 30.6^2-c	95.6 ± 29.9^2-c	4008
1 mg/kg	70.8 ± 18.3^2-c	71.8 ± 20.9^2-c	67.5 ± 17.7^2-c	71.2 ± 19.9^2-c	3155
10 mg/kg	86.5 ± 19.3^2-c	85.5 ± 16.9^2-c	65.6 ± 27.1^2-c	75.2 ± 22.3^2-c	3480
30 mg/kg	57.5 ± 4.3^2-c	55.6 ± 0.1^2-c	58.8 ± 8.5^2-c	56.8 ± 7.1^2-c	2574
Lisinopril
5 mg/kg	2.6 ± 1.4^2-d	2.1 ± 1.8^2-d	2.1 ± 1.8^2-d	3.3 ± 3.4^2-d	104
10 mg/kg	6.7 ± 3.1^2-c ^2-d	5.4 ± 3.1^2-c ^2-d	6.1 ± 2.8^2-c ^2-d	5.7 ± 5.7^2-d	267